ClinicalTrials.gg
CompletedNCT02858817Updated Jul 15, 2019

Safety and Protective Efficacy of IV Immunization With Cryopreserved PfSPZ Under A/P Chemoprophylaxis

A Phase 1 interventional study of atovaquone/proguanil 250mg/100mg (A/P) and PfSPZ Challenge (NF54) in Malaria, sponsored by University Hospital Tuebingen. Completed. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2019-07-15.

Sponsored by University Hospital Tuebingen · Phase 1, Interventional, and Prevention

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
30
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
All
01

Study summary

Single center, randomized, placebo-controlled, double-blinded trial using PfSPZ Challenge (NF54) under A/P chemoprophylaxis for immunization and PfSPZ Challenge (NF54) and PfSPZ Challenge (7G8) for repeat CHMI.

A total of 30 adult, healthy, malaria naïve volunteers will receive three injections by Direct Venous Inoculation (DVI) of either placebo (n = 10), 51,200 PfSPZ Challenge (NF54) (n = 10), or 150,000 PfSPZ Challenge (NF54) (n = 10) under chemoprophylaxis with A/P at 4 week intervals. The placebo will be normal saline (0.9% NaCl).

Ten weeks after the last dose of PfSPZ Challenge (NF54) for immunization, volunteers will undergo first CHMI and followed until asexual blood stage parasitemia, detected by quantitative real time PCR (qPCR) or thick blood smear microscopy. If parasitemic, they will be treated with A/P (used in this case as a standard treatment regimen). In the event of no parasitemia, volunteers will be followed until Day 28 post-CHMI and will not receive A/P.

Sixteen to forty-four weeks after the last immunization, a second CHMI will be administered to assess longevity and cross-strain protection. All volunteers will be followed up to 28 days post-inoculation. Those developing parasitemia will be treated with A/P.

Volunteers of Group A will have CHMI with PfSPZ Challenge (NF54) followed by PfSPZ Challenge (7G8). Volunteers of Group B will have CHMI with PfSPZ Challenge (NF54) or PfSPZ Challenge (7G8) followed by PfSPZ Challenge (7G8). In the case that protective efficacy in Group A is ≥75% CHMI sequence will be 7G8-7G8. In the case that protective efficacy against homologous Challenge in Group A is \<75%, volunteers will receive the same sequence as in Group A (NF54-7G8).

02

Conditions studied

  • Malaria

Browse trials for

03

In context

Malaria

1,186 studies on the registry are indexed under Malaria; 80 are open to participants now.

This study's enrollment of 30 is below the median of 252 across 939 interventional studies indexed under Malaria.

Browse Malaria studies →

Lead sponsor

University Hospital Tuebingen is the lead sponsor of 492 studies on the registry; 110 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy adults aged 18 to 45 years.
  • Able and willing (in the Investigator's opinion) to comply with all study requirements.
  • Willing to allow the investigators to discuss the volunteer's medical history with their general practitioner if required.
  • Residence in Tübingen or surroundings for the period of the trial.
  • Women only: Must agree to practice continuous effective for the duration of the study (a method which results in a low failure rate; i.e. less than 1% per year).
  • Agreement to refrain from blood donation during the course of the study and after the end of their involvement in the study according to the local and national blood banking eligibility criteria (currently four years in Germany).
  • Provision of written to receive PfSPZ Challenge for immunization and subsequently for CHMI.
  • Reachable (24/7) by mobile phone during the immunization and CHMI period.
  • Willingness to take A/P during immunization and a curative antimalarial regimen following CHMI.
  • Agreement to stay overnight for observation during the period of intensive follow-up post-challenge if required.
  • Answer all questions on the informed consent quiz correctly.
  • A 18-35.

Exclusion criteria

Exclusion Criteria:

  • History of P.falciparum malaria.
  • Planned travel to malaria endemic areas during the study period.
  • Use of systemic antibiotics with known antimalarial activity within 30 days of study enrollment (e.g. trimethoprim-sulfamethoxazole, doxycycline, tetracycline, clindamycin,erythromycin, fluoroquinolones, or azithromycin).
  • Receipt of an product in the 90 days preceding enrollment, or planned receipt during the study period.
  • infection.
  • Any confirmed or suspected or immunodeficient state (e.g. repeated and/or unusual infections),history of infection caused by opportunistic organisms any infection or combination of infections that suggest underlying immunodeficiency, history of meningitis, encephalitis, septic shock, life-threatening soft tissue infection, more than one pneumonia, asplenia and/or chronic (more than 14 days) immunosuppressant medication within the past 6 months (inhaled and topical are allowed)).
  • Use of immunoglobulins or blood products within 3 months prior to enrolment.
  • Known (or signs consistent with) sickle cell anemia, sickle cell trait, thalassemia or thalassemia trait, glucose-6-phosphate dehydrogenase deficiency.
  • Pregnancy, lactation or intention to become pregnant during the study.
  • to the use of the following antimalarial medications: A/P, artemether-lumefantrine
  • History of cancer (except basal cell carcinoma of the skin and cervical carcinoma in situ).
  • History of serious psychiatric condition that may affect participation in the study
  • Any other serious chronic illness requiring hospital specialist supervision.
  • Suspected or known current alcohol abuse as defined by an alcohol intake of greater than 60 g (men) or 40 g (women) per day or a carbohydrate deficient transferrin (CDT) level ≥2.5%.
  • Suspected or known injected drug abuse in the 5 years preceding enrollment.
  • Positive for surface antigen (HBs-antigen).
  • Seropositive for virus (antibodies to HCV).
  • Falling in moderate risk or higher categories for fatal or non-fatal cardiovascular event within 5 years (>10%) determined by non-invasive criteria for cardiac risk 84.
  • Abnormal on screening: pathologic Q wave and significant ST-T wave changes, left ventricular hypertrophy, arrythmias, left bundle branch block, secondary or tertiary AV block
  • A /QTcB interval >450 ms.
  • Volunteers unable to be closely followed for social, geographic or psychological reasons.
  • CrCL \<30ml/min
  • History of seizure (except uncomplicated febrile convulsion at childhood)
  • Immunization with more than 3 other vaccines within the past month
  • Any other significant disease, disorder, finding at medical history, biochemistry, hematology tests, urine analysis results or at clinical examination which, in the opinion of the investigator, may significantly increase the risk to the volunteer because of participation in the study, affect the ability of the volunteer to participate in the study or impair interpretation of the study data.
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

05

Study design

Phase
Phase 1
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Factorial assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
30 participants (actual)

Study arms

  • Experimental
    51,200 PfSPZ

    Three injections of 51,200 PfSPZ Challenge (P. falciparum strain: NF54) under chemoprophylaxis with atovaquone/proguanil 250mg/100mg (A/P) at 4 week intervals

    Drug: atovaquone/proguanil 250mg/100mg (A/P) · Biological: PfSPZ Challenge (NF54)

  • Experimental
    150,000 PfSPZ

    Three injections of 150,000 PfSPZ Challenge (P. falciparum strain: NF54) under chemoprophylaxis with atovaquone/proguanil 250mg/100mg (A/P) at 4 week intervals

    Drug: atovaquone/proguanil 250mg/100mg (A/P) · Biological: PfSPZ Challenge (NF54)

  • Placebo comparator
    Placebo

    Three injections of NaCl 0,9% solution under chemoprophylaxis with atovaquone/proguanil 250mg/100mg (A/P) at 4 week intervals

    Drug: atovaquone/proguanil 250mg/100mg (A/P) · Other: NaCl 0,9%

Interventions

  • Drugatovaquone/proguanil 250mg/100mg (A/P)

    Combination drug for chemo-prophylaxis or treatment of malaria

    Also known as: Malarone

  • BiologicalPfSPZ ChallengeStudies of PfSPZ ChallengePfSPZ Challenge pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    cryo-preserved Plasmodium falciparum sporozoites injected by venous inoculation

  • OtherNaCl 0,9%

    0.9% NaCl solution for injection

    Also known as: Placebo

06

What researchers measure

Primary outcomes

  1. Number or occurrence of related Grade 3 and 4 adverse events (AEs) and serious adverse events (SAEs)

    Time frame: from time of first administration of A/P until the last follow up visit, 414 days after first administration

Secondary outcomes

  1. Occurrence of any related AE

    Time frame: from time of first administration of A/P until the last follow up visit, 414 days after first administration

  2. Proportion of protected volunteers

    . Protection is defined as the absence of parasites in the peripheral blood for 28 days following first and second CHMI with PfSPZ Challenge (NF54) and PfSPZ Challenge (7G8) in volunteers receiving PfSPZ-CVac with A/P. Parasitemia is defined as at least one qPCR result above 100 parasites per mL among three positive results at least 12 hours apart or as a positive thick blood smear. Statistical testing is hierarchical: 1) protection against first CHMI, 2) protection against second CHMI.

    Time frame: From time of PfSPZ challenge administration until 28 days after PfSPZ challenge

Other outcomes

  1. Time-to-parasitemia in volunteers who receive immunization using PfSPZ Challenge or placebo under A/P chemoprophylaxis and become parasitemic within 28 days following CHMI with PfSPZ Challenge (NF54) or PfSPZ Challenge (7G8).

    Time frame: Until 28 days after challenge

  2. Time-to-parasitemia in placebo recipients following 2nd versus 1st CHMI (carry-over effect).

    Time frame: Until 28 days after challenge

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2016 to primary completion in Nov 2017, 11 months.

Of 64 non-industry phase 1 interventional studies under Malaria, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 24. This study's 11 months is below that.

Counting every sponsor, half of 93 studies reached it within 13 months; a quarter within 7 and three quarters within 20.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 28, 2016
First posted
Aug 8, 2016
StartActual
Nov 28, 2016
Primary completionActual
Nov 16, 2017
CompletionActual
Nov 16, 2017
Last update
Jul 15, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 15, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02858817
Collaborators
Sanaria Inc.
Responsible party
Sponsor
First posted
Aug 8, 2016
Start date
Nov 28, 2016
Primary completion
Nov 16, 2017
Completion
Nov 16, 2017
Last update
Jul 15, 2019

Study contacts

Peter G Kremsner, Prof
principal investigator · University Hospital Tübingen, Tübingen, Germany

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion